Analysis of 132 group A streptococcal (GAS) isolates from 151 invasive episodes, including streptococcal toxic shock syndrome (STSS), from 1983 to 1995 showed great genetic variation by use of T serotyping in combination with restriction fragment length polymorphism. In contrast, genetically homogenous T1M1 isolates appeared in epidemic patterns with significantly increased risk of STSS. The speA gene, with the allelic variants speA2 and speA3 carried by the T1M1 and T3M3 serotypes, respectively, was strongly associated with STSS. Infection with a GAS isolate carrying speA, alcohol abuse, and malignancy recently treated with cytostatic drugs were factors independently related to STSS. Neutralization of SpeA lymphocyte mitogenicity was totally absent in sera from patients with STSS and low in sera from persons with uncomplicated bacteremia compared with levels in sera from uncomplicated erysipelas. Neutralization of SpeB was significantly lower in sera of patients with STSS than in sera from persons with bacteremia or erysipelas.
exotoxins (Spe) A and B [14] [15] [16] . SpeA is produced particularly by M1 and M3 isolates, and new speA allelic variants have been identified in recent M1 and M3 isolates [17] . The mitogenic activity of SpeA3, associated with recent M3 isolates, is significantly higher than that of other allelic variants [18] . Furthermore, M1 isolates from Scandinavia, Finland, North America, and other parts of the world are identical or closely related clones [15, 19] . In contrast, another study reported that invasive GAS infections and STSS are also caused by genetically heterogeneous GAS isolates of serotypes other than M1 and M3 [20] . Host genetic factors, acquired immunity against relevant virulence factors, underlying chronic disease, and other factors are probably important for the development of severe GAS disease [16, 21, 22] .
The present study was undertaken to analyze the molecular characteristics of invasive GAS isolates from a limited geographic area over a relatively long period and to investigate the corresponding human immunity against Spes. tibodies against various other microorganisms before invasive GAS infection was diagnosed. In addition, GAS isolates and sera from 10 patients collected during a prospective study of erysipelas were included [24] . These GAS samples were isolated from a superficial site; the patients had no bacteremia and an uncomplicated course and were regarded as a group with a good prognosis compared with persons in the bacteremia group.
Fifteen T1M1 isolates obtained from blood cultures in other parts of Sweden during 1980-1986 and 28 T1M1 isolates collected from throat cultures of patients with upper respiratory infections during the 1982 winter season were obtained from the Swedish Institute for Infectious Disease Control. These isolates were analyzed in parallel with the 27 T1M1 isolates from the 151 invasive episodes.
Restriction fragment length polymorphism (RFLP) . Five colony-forming units of each isolate were picked from a blood agar plate and grown overnight in 3 mL of Todd-Hewitt broth, and 500 mL of the culture was pelleted by centrifugation. The pellet was washed in 500 mL of PIV buffer containing 1 mM NaCl and 10 mM Tris-HCl, pH 7.6, and resuspended in 100 mL of PIV buffer. To the bacterial suspension was added 100 mL of 2% agarose, and 100 mL of this suspension was molded into a plug. After solidification, the plugs were incubated 3-4 h at 37ЊC in freshly made lysis buffer containing 40 mL of lysozyme (concentration, 25 mg/ mL; Sigma Chemical, Stockholm) and 40 mL (5000 U/mL) mutanolysin (Sigma). The buffer was removed and replaced by 1 mL of fresh proteinase K buffer containing 0.5 M EDTA, pH 7.6, 0.5% sarkosyl, and 1 mg/mL proteinase K (Boehringer Mannheim, Stockholm) and incubated at 50ЊC overnight. The proteinase K buffer was removed, and the plugs were washed five times in 10 mM Tris-HCl and 1 mM EDTA, pH 7.6, at 30-to 60-min intervals. A 4-mm slice of each plug was digested with 20 U of SmaI in restriction buffer supplied by the manufacturer (MBI Fermenta; Labassco, Gothenburg, Sweden) and placed at room temperature overnight. The excess restriction buffer was aspirated, and the plugs were transferred to wells in a 1% agarose gel and subjected to pulsed-field gel electrophoresis in a contour-clamped homogenous electric field apparatus (Gene Path System; Bio-Rad, Richmond, CA). Gels were stained with ethidium bromide and photographed under UV illumination. The banding patterns of the strains within specific T serotypes were compared by visual inspection. A difference of у1 band between strains of the same T type was considered a separate RFLP type within that T serotype.
Polymerase chain reaction (PCR) analysis of speA. Five to 10 colonies were picked from a blood agar plate, resuspended in 50 mL of sterile distilled water in a micro-test tube and heated for 5 min at 100ЊC. After centrifugation, 10 mL of the supernatant was used as template in the PCR reactions. Reaction conditions were 0.2 mM dNTPs, 20 pmol of each primer with 0.5 U of Taq polymerase buffer with 1.5 mM MgCl 2 (MBI Fermenta; Labassco), and bovine serum albumin (0.17 mg/mL). Amplification was done on a thermal cycler with annealing temperature of 55ЊC (PTC-200; MJ Research, Scandinavian Diagnostic Services, Falkenberg, Sweden). We used forward primer speA 813-837; 5 -ATGGAAAA-CAATAAAAAAGTATTG-3 and reverse primer speA 1545-1569; 5 -TTACTTGGTTGTTAGGTAGACTTC-3 [25] . Positive control for these experiments was the streptokinase gene (ska) amplified with forward primer ska 453-477; 5 -AACCTTGCCGACCC-AACCT-3 and reverse primer ska 770-791; 5 -TCCATTGGT-AAAATCGTACGG-3 [26] . The PCR products were separated with electrophoresis on 0.7% agarose gels.
Determination of speA allelic variants. We determined the speA allele variant carried by 6 T1M1 and 4 T3 isolates and in the 3 speA-positive isolates belonging to other serotypes, 2 T6 and 1 T nontypeable. A sequence 1200 bp, including the specific mutation sites defining the speA2 and speA3 allelic variants, was analyzed by automated sequencing [17] . PCR primers for sequencing were 5 -GTTTCAGGGCCAAATTATG-3 (forward) and 5 -GGATAC-CATCGATTGATAC-3 (reverse). Templates for sequencing primers were the PCR products acquired by the same primers as used for the identification of speA as described above.
Immunologic detection of SpeA, SpeB, and SpeF. Semiquantitative determination of the production of SpeA, SpeB, and SpeF was determined by an immunodot blot method, as described elsewhere [16] . In brief, bacterial cultures were grown overnight at 37ЊC, and the optical density at 500 nm was corrected to 1.5 for all strains by dilution of the bacterial culture with fresh growth medium. After 5 mL of the bacterial culture was centrifuged, the supernatant was collected and precipitated by ethanol at Ϫ20ЊC for 16 h. The precipitate was collected by centrifugation, resuspended in 1.0 mL 0.15 M NaCl and 10 mM NaAc, pH 4.0, dialyzed against distilled H 2 O overnight, and lyophilized and resuspended in 0.5 mL of H 2 O. A dot blot technique was used, with the toxin preparation applied on nitrocellulose filters in dilution series from 1/4 to 1/1024. The toxins were detected by rabbit anti-toxin antibodies. An alkaline phosphatase-conjugated affinity-purified goat anti-rabbit IgG (8612-0081; Cappel, West Chester, PA) was used as a secondary antibody.
Exotoxin neutralization by patient sera. Neutralization of Speinduced lymphocyte proliferation was done as described previously [22] . Serum samples drawn in the acute phase of the disease were analyzed. The sera usually had been collected for analysis of the presence of antibodies directed against hepatitis or influenza viruses and had been stored at Ϫ20ЊC. Six sera were identified from persons who developed STSS and 25 from persons with bacteremia with varying focal infections but with no signs of STSS. Acute-phase sera from 10 subjects with erysipelas due to GAS infection but with no bacteremia and no signs of STSS were used as controls [24] . Neutralization of the Spe mitogenic activity at a concentration of 5 ng/mL was tested in the presence of 5% human serum (HS) and fetal calf serum (FCS) to a final serum concentration of 10% in microtiter wells containing freshly prepared lymphocytes. 5 1.5 ϫ 10 Unstimulated cells were used as background control, and percentage of inhibition by patient sera of cell proliferation was related to count per minute (cpm) values obtained when lymphocytes were stimulated in the presence of 5 ng/mL Spe and FCS to a final concentration of 10% without patient serum. Percentage of inhibition of Spe-induced mitogenicity was calculated as (cpm 1 Ϫ [ Ϫbackground)/(cpm Ϫbackground) 00. HS ϭ Spe FCS ϭ Spe ] ϫ 1 Statistical analysis. Differences in serum neutralization titers between patient categories against the exotoxins were analyzed by Wilcoxon rank sum test. The background medical data on underlying chronic diseases and clinical features of the 151 invasive episodes as well as T types of the 135 GAS isolates and their relation to an outcome of STSS or mortality have been reported in detail [23] . Data from the present study on results of speA PCR was Ϫ isolates, RFLP patterns XIX-XXII; 17 and 18, T28OF ϩ isolates, RFLP patterns XXVI-XXVII. Size markers used as L ladder: pulsed-field gel marker, 48.5-727.5 kb. Table 1 . T type distribution, opacity factor (OF) production, restriction fragment length polymorphism (RFLP) pattern, presence of speA gene among invasive group A streptococcal isolates, and number of associated streptococcal toxic shock syndrome episodes. included with the previous data in a logistic regression analysis of the relation of speA to STSS or mortality.
Results
In total, 132 clinical isolates of GAS from 151 episodes of invasive infection were analyzed for T/M serotype by T serotyping and opacity factor (OF) production, RFLP pattern, and carriage of the speA gene as outlined in table 1 .
Genetic variation of GAS isolates by RFLP pattern within T types. Serotype distribution and RFLP patterns within individual T types are shown in table 1. RFLP was performed on 132 GAS strains from the 151 invasive episodes. The overall genetic variation was great within most T types, as is shown in table 1. We identified 19 different T types and 14 T nontypeable isolates; each T type had 1-9 RFLP patterns. Each of the 9 T28 isolates had an individual RFLP pattern (figure 1). Among the 14 T nontypeable isolates, 11 different RFLP patterns were identified. Somewhat less genetic variability was seen in T3 OF-negative (T3M3) and T8 isolates.
The T1M1 isolates (T1, OF negative) appeared in two epidemic waves during 1986-1990 (peak, 1988 ) and again in 1993-1995, as described elsewhere [23] . It was the most common serotype and comprised 20% (27/135) of all available isolates but showed less genetic variability. Of the 27 T1M1 isolates, 25 had identical RFLP patterns by SmaI restriction analysis (pattern I, figure 1), regardless of the year of isolation. (table 1) , and all 132 isolates were positive when tested for the ska gene. Of the 27 T1M1 isolates, 25 (93%) were speA PCR positive. The other isolates associated with speA were of the T3 OF-negative (T3M3) serotype. All 9 T3M3 isolates and 1 T3/13/B3264 OF-negative isolate were speA positive. The only additional speA-positive isolates were 2 T6 and 1 T nontypeable. None of the 75 isolates belonging to other serotypes were positive by PCR for speA (table 1) .
Allelic variants of the speA gene. The 6 T1M1 isolates from bacteremia patients all harbored the speA2 allele, and all had the same RFLP pattern. This RFLP pattern was identical to that found in all T1M1 isolates carrying the speA gene. Four of the 6 isolates were from persons who developed STSS. The 4 T3 isolates analyzed all had different RFLP patterns, but sequencing of the speA gene revealed that they carried the speA3 allele. One of the 4 patients developed STSS. The 1 T nontypeable isolate that was speA PCR positive also carried the speA3 allele. This patient developed STSS. The 2 T6 isolates positive for speA both harbored a speA allele corresponding to speA4, with a 97% and 98% sequence identity, respectively, over the analyzed nucleotide sequence.
Immunologic detection of SpeA, SpeB, and SpeF production in invasive GAS isolates. A semiquantitative analysis of 61 isolates was done for the production of the protein exotoxins SpeA, SpeB, and SpeF (table 2). SpeA production was analyzed in isolates with a positive speA PCR and showed relatively low titers (table 2) . Titers of SpeB and SpeF production were usually higher than SpeA titers (table 2). SpeB in particular was produced in high amounts by many isolates; 34 (56%) of 61 had a titer of 256 or 1024. No differences were seen in titers of any of the exotoxins between persons with bacteremia with STSS and those with uncomplicated bacteremia.
Neutralization of Spe mitogenicity by patient sera. Sera from 31 persons with bacteremia (25, uncomplicated courses; 6, STSS) were analyzed for the ability to neutralize the lymphocyte mitogenic properties of SpeA, SpeB, and SpeF. All but 4 of the 31 sera were drawn within 4 days of diagnosis of the infection. The other 4 sera were drawn 0.5-3 months before the sepsis episode during hospital admission for other disease episodes. Sera drawn within 4 days of admission from 10 patients with erysipelas with GAS isolated from superficial sources (e.g., wound or throat, but not from blood, and with no clinical signs of STSS) were analyzed as controls. Clinical and laboratory data for these 41 patients are shown in table 3. Neutralization titers against SpeA, SpeB, and SpeF in the 3 patient categories (uncomplicated erysipelas without bacteremia, uncomplicated bacteremia, and bacteremia with STSS) are shown in figure 2 .
The average neutralization level against SpeA was higher in sera from patients with erysipelas (44.7%), compared with 18.4% and 0% in sera from persons with uncomplicated bacteremia or STSS, respectively (figure 2A). All 6 sera (100%) from patients who developed STSS totally lacked neutralization ability of SpeA mitogenicity, compared with 18 (72%) of 25 bacteremia and 1/10 erysipelas patient sera. Compared with sera from patients with erysipelas, the neutralization level against SpeA was significantly lower in sera from persons with STSS and in those with uncomplicated bacteremia (P ϭ .002 and .006, respectively, Wilcoxon rank sum test). Sera from 5 other persons who developed STSS where analyzed, but 4 had been given freshly frozen plasma before serum were drawn, and 1 had serum drawn several months after the STSS episode. These sera were not included in the above analysis. Nevertheless, 3 of these 5 sera totally lacked the ability to neutralize SpeA mitogenic properties. This may indicate the presence of free circulating toxin binding to exogenously supplied antitoxin antibodies. The ability of patient serum to neutralize SpeA sera would be of importance only when the infecting GAS isolate encoded the SpeA gene. Four of the 6 patients with STSS and 7/25 with uncomplicated bacteremia were infected with an speA PCRpositive GAS isolate. All 4 STSS patient sera lacked SpeA neutralizing antibodies, whereas bacteremia patients had an average SpeA neutralization titer of 35%.
SpeB neutralization in sera from the erysipelas patients averaged 62.4%, compared with 58.7% in sera from patients with bacteremia and 13.8% in STSS sera (figure 2B). The SpeB neutralization level was not significantly different between persons with erysipelas and sepsis ( , Wilcoxon rank sum test). P ϭ .8 However, the STSS patient sera showed significantly lower SpeB neutralization than sera from persons with erysipelas ( ) or bacteremia with no STSS ( ). P ϭ .003 P ϭ .01 SpeF neutralization was high in sera from all 3 patient groups, although sera from persons with STSS again had a slightly lower neutralization ability: erysipelas group, 80% on average; bacteremia group, 73%; and STSS group, 64% (P1 , one-way analysis of variance, figure 2C logistic regression). Patient data on underlying chronic disease and T serotype [23] were analyzed together with the speA data from the present study in a multivariate logistic regression model using backward step-wise regression. In this model, STSS was independently associated with infection with an isolate carrying the speA gene (OR, 32.6; 95% CI, 6.0-607; ), P ϭ .001 alcohol abuse (OR, 37.2; 95% CI, 5.6-745;
), and ma-P ϭ .001 lignancy recently treated with cytostatic drugs (OR, 40.0; 95% CI, 3.2-988; ). In contrast to the development of STSS, P ϭ .006 a positive speA PCR for the infecting isolate was not associated with mortality.
Discussion
STSS, a multiorgan failure syndrome, develops in a proportion (13% in this study) of persons with an existing invasive infection, although it has also been associated with noninvasive infections [10, 27, 28] . Hypotheses about the recent resurgence of serious GAS infections usually suggest the importance of bacteriologic factors, such as the spread of invasive clones carrying speA [13] [14] [15] , or emphasize epidemiologic and host factors [20] [21] [22] . A combined view would be that most GAS clones generate invasive episodes in proportion to their spread in the population but differ in their ability to induce STSS [23] and other complications because of differences in virulence properties or differences in the host's acquired humoral immunity against these virulence factors This study demonstrates that the genetic variability of invasive GAS strains is great overall, as is shown by the distribution of T types and RFLP patterns within specific T types. Serologic typing using T antisera is not as discriminating as M typing. However, M typing of sera is difficult, and many isolates are not M typeable. Sequencing the emm gene may be a relevant future alternative to M typing [29] but was not used in this study. Because our main interest was to analyze genetic diversity of the whole genome of the GAS isolates, we used T serotyping in combination with RFLP. Among 132 strains from these 151 invasive episodes, 29 different combinations of T type/OF production were found, and the number of RFLP patterns within each T type varied between 1 and 9. Among the 14 T nontypeable isolates, no less than 11 different RFLP patterns were found. This is consistent with previous findings of great genetic variability among invasive isolates [20] .
GAS isolates from patients developing STSS also showed genetic variation in 150% of the cases; 11/19 STSS episodes were caused by a unique clone as judged by T type/OF production and RFLP analysis. The other 8 STSS cases were caused by T1M1 strains with RFLP pattern I. Of the 27 T1M1 invasive isolates, 25 had SmaI pattern I, as did all 15 T1M1 invasive isolates collected in Sweden during 1980-1986 and the 28 T1M1 throat isolates from 1982-1983. These isolates are most likely of a common clonal origin. Only 2 T1M1 isolates showed a different RFLP pattern, and both lacked the phageencoded speA gene. Whether these isolates also differ in other genes requires further study.
The T1M1 GAS, which appeared in epidemic waves in 1988-1989 and again in 1993-1995, induced a proportionately increased number of STSS cases compared with other serotypes [23] . Hence, this study, which evaluated a 13-year period in a limited geographic area, revealed a pattern of a generally low background incidence of invasive GAS infections and STSS due to genetically very diverse isolates. On this were superimposed two distinct waves of disease due to a homogenous T1M1 clone with an increased risk of STSS. It is not evident from our study whether the T1M1 clone caused disproportionately more invasive infections overall compared with other GAS isolates, because we had no control group of noninvasive infections. Both in Finland and in Sweden during these epidemic episodes, the T1M1 isolates from noninvasive throat infections and invasive infections increased proportionately [19, 30] and were genetically similar [19] . T1M1 and T3 were the only serotypes carrying the speA gene, except for 2 T6 and 1 T nontypeable isolate. In agreement with previous observations, all T1M1 isolates carried the speA2, and all T3 isolates carried the speA3 allelic variant. Of interest, in the only patient infected with a speA-positive T nontypeable GAS who developed STSS, the allele was speA3, which has a greater mitogenic capacity than other allelic variants [18] . None of the invasive episodes caused by a T nontypeable speA PCRnegative isolate was associated with STSS. The 2 T6 speApositive isolates both carried the speA4 allelic variant, but neither patient developed STSS.
The association of speA with STSS was also statistically highly significant (OR, 5.7;
, univariate logistic re-P ϭ .001 gression) when patient background variables were included in a logistic regression model (OR, 32.6;
). The inclusion P ϭ .001 of speA in the logistic regression model eliminated the statistically significant association of the T1M1 serotype with STSS, and the association in the multivariate model was stronger for speA than for the T1M1 serotype. Therefore, it seems likely that the speA gene, rather than the serotype itself, confers the extra risk for STSS. The probable direct importance of SpeA for the development of STSS was further emphasized by the total inability of STSS patient sera to neutralize the lymphocyte mitogenic properties of SpeA. These findings are in agreement with the known biologic properties of SpeA as a superantigen [31] . In a study that compared the capacity of SpeA, SpeB, and SpeF to induce cytokine expression in lymphocytes, SpeA was the most potent inducer of interferon-g and tumor necrosis factor-b production [32] .
The influence of SpeA on the outcome of invasive GAS infections may be further accentuated when isolates harboring this phage-encoded toxin appear in epidemic patterns and carry a new allelic variant of the toxin, as with recent M1 and M3 isolates. Population immunity may be low under such circumstances, setting the scene for an increased number of episodes with a toxic shock-like outcome.
Toxin production as detected by the semiquantitative dot blot method showed low titers for SpeA. This finding is consistent with previous studies from Europe [16] . However, expression of SpeA is dependent on temperature [33] , and a recent study indicates that SpeA expression may undergo phase variation, making in vitro analysis less representative of in vivo conditions [34] . SpeB titers were generally higher than those of SpeA by the semiquantitative method. SpeB is chromosomally encoded, and the gene is believed to be present in all GAS isolates [14] . However, the expression of speB is influenced by external factors [35] .
Toxin neutralization by patient sera revealed total lack of neutralization of SpeA lymphocyte mitogenic properties in each of the 6 patients with STSS and low levels in patients with uncomplicated bacteremia, whereas it was significantly higher in sera from patients with uncomplicated erysipelas without bacteremia. Although early studies implicated SpeA as an important factor in the pathogenesis of STSS [36] , previous studies from this laboratory have not identified low SpeA neutralization titers among persons with severe disease [16, 22] . This may be because of the few patients investigated and low statistical power.
Neutralization of SpeB was significantly lower among persons with STSS than in those with uncomplicated bacteremia ( ) or erysipelas ( ), which is in line with results P ϭ .01 P ϭ .003 from previous studies in this laboratory and further emphasizes SpeB as an important factor in the pathogenesis of STSS. However, the pathogenetic mechanisms leading to circulatory shock may involve mechanisms other than superantigenic ones, such as the activation of kinins in plasma [37] .
SpeF also is believed to be expressed by all GAS strains. This toxin has superantigenic properties [38] , but whether it is involved in the pathogenesis of serious manifestations of GAS disease is not clear. Previous studies have shown low titers of SpeF neutralizing antibodies in patients with invasive GAS disease [22] , but this finding was not repeated in this study. No significant difference in the SpeF neutralization ability of serum was noted between patients with STSS, uncomplicated bacteremia, and erysipelas, although titers tended to be lower in sera from STSS patients.
A recent study from Minnesota that analyzed molecular characteristics of invasive GAS infections had results similar to ours [39] . The epidemic M3 isolates were genetically homogenous and carried the speA3 allele, whereas nonepidemic isolates were genetically more diverse [39] . A few isolates from that study also carried genes for speC and streptococcal superantigen, but the importance of these other toxin genes for the development of severe GAS disease is not known [40] .
In conclusion, this study showed that endemic invasive GAS infections including episodes of STSS were caused by GAS isolates with great genetic variability, as is shown by highly variable RFLP patterns within most T types. In contrast, genetically homogenous T1M1 isolates appeared in epidemic waves, causing invasive episodes with significantly increased risk of STSS. The speA gene was associated primarily with T1M1 and T3 isolates, but regression analysis indicated a strong association of STSS with speA rather than serotype. T1M1 isolates carried the speA2 and T3 isolates the speA3 allelic variants. The only T nontypeable speA-positive isolate carried the speA3 allele, and this patient developed STSS. In addition, sera from persons with STSS totally lacked the ability to neutralize SpeA. We believe this study from a confined geographic area that covered a large time interval shows a strong, but not exclusive, association of SpeA with the development of STSS. Serum neutralization of SpeB was significantly lower in sera from patients with STSS compared with those with uncomplicated bacteremia or erysipelas, giving further support for this toxin as an important factor in the pathogenesis of STSS.
